Cingulate (CING) to Release Earnings on Monday

Cingulate (NASDAQ:CING) is anticipated to release its earnings data before the market opens on Monday, March 24th. Analysts expect Cingulate to post earnings of ($1.48) per share for the quarter.

Cingulate Trading Down 3.2 %

Cingulate stock opened at $3.96 on Friday. The firm has a 50 day simple moving average of $4.34 and a 200-day simple moving average of $4.55. Cingulate has a 12-month low of $1.80 and a 12-month high of $20.83.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Roth Mkm assumed coverage on shares of Cingulate in a research report on Friday, January 10th. They issued a “buy” rating and a $12.00 price target for the company. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Cingulate in a report on Thursday, March 6th. Finally, Roth Capital upgraded shares of Cingulate to a “strong-buy” rating in a report on Friday, January 10th.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.